STAT reporters discuss investors' interest in autoimmune disease, GLP-1 supply issues, and big moments from #STATSummit.

FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking ...

T here's always a new headline about weight-loss drugs, whether it's sharing new data on how many pounds someone has lost or ...

In that spirit, let's consider two biotech companies that could potentially deliver incredible returns next year: Recursion ...

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

Eli Lilly (NYSE: LLY) plans to invest $206M to expand its Suzhou, China site for Type 2 diabetes and obesity drugs. The ...

The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

Investorideas , a global news source and expert investing resource, announces today's roundup of <a target=_blank href= ...

Eli Lilly (NYSE: LLY) has partnered with the UK government, investing £279 million ($340 million) to address public health ...

The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech ...

If you're like the vast majority of individual investors, you've never heard of Scholar Rock, apitegromab, or the ...